Drug intelligence / Profile preview

INCA041798

Development stage: Preclinical
Lead developer: Incyte
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

INCA041798 is an investigational, next-generation monoclonal antibody developed by Incyte that targets mutant calreticulin (mutCALR). It is designed with an extended half-life and exhibits potent activity across clinically relevant mutCALR variants. The antibody is being developed for the treatment of myeloproliferative neoplasms (MPNs), such as myelofibrosis and essential thrombocythemia, where mutant calreticulin acts as a key oncogenic driver. As a successor to Incyte's first-in-class mutCALR-directed antibody, INCA033989, INCA041798 is currently in preclinical development.

Targets

CALR (Calreticulin)

Beyond the preview

Go deeper on INCA041798.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INCA041798.